Tentative clinical breakpoints and epidemiological cut-off values of nemonoxacin for Streptococcus pneumoniae and Staphylococcus aureus isolates associated with community-acquired pneumonia
Objectives: To determine the minimum inhibitory concentration (MIC) distribution, epidemiological cut-off (ECOFF) values and clinical breakpoints (CBPs) of nemonoxacin, a non-fluorinated quinolone, for community-acquired pneumonia (CAP)-related Streptococcus pneumoniae and Staphylococcus aureus. Met...
Main Authors: | Shio-Shin Jean, Li-Wen Chang, Po-Ren Hsueh |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2020-12-01
|
Series: | Journal of Global Antimicrobial Resistance |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2213716520302800 |
Similar Items
-
Pharmacokinetics and Pharmacodynamics of Nemonoxacin in a Neutropenic Murine Lung Infection Model Against Streptococcus Pneumoniae
by: Xin Li, et al.
Published: (2021-05-01) -
The efficacy and safety of nemonoxacin compared with levofloxacin in the treatment of community-acquired pneumonia: a systemic review and meta-analysis of randomized controlled trials
by: Chang SP, et al.
Published: (2019-02-01) -
Safety and efficacy of nemonoxacin versus levofloxacin in the treatment of community-acquired pneumonia: results of phase III, multicenter, randomized, double-blind, active-controlled, non-inferiority trial
by: Kozlov R.S., et al.
Published: (2018-11-01) -
Contributions to an understanding of community-acquired pneumonia
by: Feldman, Charles
Published: (2012) -
Mechanisms of Naturally Acquired Immunity to Streptococcus pneumoniae
by: Elisa Ramos-Sevillano, et al.
Published: (2019-03-01)